SCORE Search Results Details for Application 10613739 and Search Result us-10-613-739-1.rng.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10613739 and Search Result us-10-613-739-1.rng.

start

Go Back to previous page

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 30, 2005, 23:56:45 ; Search time 267 Seconds
(without alignments)
599.073 Million cell updates/sec

Title: US-10-613-739-1
Perfect score: 24
Sequence: 1 tcgtcgtttcgtcgttttgtcgtt 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4996997 seqs, 3332346308 residues

Total number of hits satisfying chosen parameters: 9993994

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_21:*
1: geneseqn1980s:*
2: geneseqn1990s:*
3: geneseqn2000s:*
4: geneseqn2001as:*
5: geneseqn2001bs:*
6: geneseqn2002as:*
7: geneseqn2002bs:*
8: geneseqn2003as:*
9: geneseqn2003bs:*
10: geneseqn2003cs:*
11: geneseqn2003ds:*
12: geneseqn2004as:*
13: geneseqn2004bs:*
14: geneseqn2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	24	100.0	24	12	ADI16114	Adi16114 Immunosti
2	24	100.0	24	12	ADK19213	Adk19213 Immunosti
3	24	100.0	24	12	ADK18990	Adk18990 Immunosti
4	24	100.0	24	12	ADK19212	Adk19212 Immunosti
5	24	100.0	24	12	ADO44306	Ado44306 Nucleotid
6	24	100.0	24	13	ADT04268	Adt04268 Novel imm

	7	24	100.0	24	13	ADT04343	Adt04343 Novel imm
	8	24	100.0	24	13	ADU23248	Adu23248 Toll-like
C	9	24	100.0	578	6	ABQ18805	Abq18805 Oligonucl
	10	24	100.0	578	6	ABQ18804	Abq18804 Oligonucl
	11	24	100.0	619	6	ABQ18198	Abq18198 Oligonucl
C	12	24	100.0	619	6	ABQ18199	Abq18199 Oligonucl
	13	24	100.0	10160	12	ADP84798	Adp84798 HIV subty
	14	23	95.8	23	12	ADI16184	Adi16184 Immunosti
	15	23	95.8	23	12	ADI16179	Adi16179 Immunosti
	16	23	95.8	24	12	ADI16162	Adi16162 Immunosti
	17	23	95.8	24	12	ADI16175	Adi16175 Immunosti
	18	23	95.8	24	12	ADI16176	Adi16176 Immunosti
	19	23	95.8	24	12	ADI16163	Adi16163 Immunosti
	20	23	95.8	24	12	ADI16177	Adi16177 Immunosti
	21	23	95.8	24	12	ADI16178	Adi16178 Immunosti
	22	23	95.8	24	12	ADK19014	Adk19014 Immunosti
	23	23	95.8	24	12	ADK19226	Adk19226 Immunosti
	24	23	95.8	24	12	ADK19225	Adk19225 Immunosti
	25	23	95.8	24	12	ADK19227	Adk19227 Immunosti
	26	23	95.8	24	13	ADT04367	Adt04367 Novel imm
	27	22.4	93.3	24	2	AAV60953	Aav60953 Unmethyla
	28	22.4	93.3	24	2	AAV47689	Aav47689 Unmethyla
	29	22.4	93.3	24	2	AAV27664	Aav27664 Immunosti
	30	22.4	93.3	24	2	AAZ41936	Aaz41936 IL-12 sec
	31	22.4	93.3	24	2	AAV83715	Aav83715 Synthetic
	32	22.4	93.3	24	2	AAV74252	Aav74252 CpG-N mot
	33	22.4	93.3	24	3	AAZ61001	Aaz61001 Nucleotid
	34	22.4	93.3	24	3	AAZ48012	Aaz48012 Immune re
	35	22.4	93.3	24	3	AAZ47876	Aaz47876 Immunosti
	36	22.4	93.3	24	3	AAA39265	Aaa39265 CpG immun
	37	22.4	93.3	24	3	AAZ47671	Aaz47671 Parasitic
	38	22.4	93.3	24	3	AAA63588	Aaa63588 Immune st
	39	22.4	93.3	24	3	AAA63586	Aaa63586 Immune st
	40	22.4	93.3	24	3	AAA63598	Aaa63598 Immune st
	41	22.4	93.3	24	3	AAC60280	Aac60280 Immunosti
	42	22.4	93.3	24	3	AAA93700	Aaa93700 Unmethyla
	43	22.4	93.3	24	4	AAC87240	Aac87240 CpG oligo
	44	22.4	93.3	24	4	AAC87232	Aac87232 Immunosti
	45	22.4	93.3	24	4	AAC87231	Aac87231 5'-amidat

ALIGNMENTS

```
RESULT 1
ADI16114
ID   ADI16114 standard; DNA; 24 BP.
XX
AC   ADI16114;
XX
DT   22-APR-2004  (first entry)
XX
DE   Immunostimulatory oligodeoxynucleotide ODN 10104 SEQ ID NO:45.
XX
KW   ds; immunostimulatory; antibacterial; antiallergic; antiasthmatic;
KW   cytostatic; virucide; fungicide; antiparasitic; interleukin antagonist;
KW   gene therapy; infectious disease; allergy; asthma; cancer.
XX
OS   Unidentified.
XX
PN   WO2004005476-A2.
XX
PD   15-JAN-2004.
XX
PF   03-JUL-2003; 2003WO-US021113.
XX
PR   03-JUL-2002; 2002US-0393880P.
PR   03-JUL-2002; 2002US-0394090P.
PR   03-JUL-2002; 2002US-0394091P.
PR   03-JUL-2002; 2002US-0394164P.
PR   03-JUL-2002; 2002US-0394193P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
```

```
PI   Krieg AM;
XX
DR   WPI; 2004-091353/09.
XX
PT   New immunostimulatory nucleic acid molecule composition comprising CpG
PT   motifs, useful for diagnosing, preventing and/or treating infectious
PT   diseases, allergies, asthma and cancers.
XX
PS   Claim 1; SEQ ID NO 45; 257pp; English.
XX
CC   The invention relates to a novel composition comprising an
CC   immunostimulatory nucleic acid molecule. A composition of the invention
CC   has antibacterial, antiallergic, antiasthmatic, cytostatic, virucide,
CC   fungicide, and antiparasitic activity. A composition may act as an
CC   interleukin antagonist-4, or interleukin antagonist-5, and may have a use
CC   in gene therapy. The methods and compositions of the present invention
CC   are useful for diagnosing, preventing and/or treating infectious disease,
CC   allergy, asthma, cancer, where the infectious disease is a herpes simplex
CC   virus, bacterial, fungal or parasitic infection, and where the cancer is
CC   a biliary tract cancer, bone cancer, brain and CNS cancer, breast cancer,
CC   cervical cancer, choriocarcinoma, colon cancer, connective tissue cancer,
CC   endometrial cancer, oesophageal cancer, eye cancer, gastric cancer,
CC   Hodgkin's lymphoma, intraepithelial neoplasms, larynx cancer, lymphomas,
CC   liver cancer, lung cancer (e.g. small cell and non-small cell), melanoma,
CC   neuroblastomas, oral cavity cancer, ovarian cancer, pancreas cancer,
CC   prostate cancer, rectal cancer, sarcomas, skin cancer, testicular cancer,
CC   thyroid cancer and renal cancer. The present sequence represents an
CC   immunostimulatory nucleic acid molecule of the invention.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 2
ADK19213
ID   ADK19213 standard; DNA; 24 BP.
XX
AC   ADK19213;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Immunostimulatory nucleic acid #259.
XX
KW   immunostimulatory nucleic acid; asthma; allergy; cancer;
KW   infectious disease; autoimmune disease; airway remodeling;
KW   chronic obstructive pulmonary disease; asthma; IL-6; interleukin-6;
KW   TNFalpha; tumour necrosis factor alpha; IFNalpha; interferon-alpha;
KW   IFNgamma; interferon-gamma; IP-10; interferon inducible protein;
KW   viral infection; bacteria infection; parasitic infection; ss.
XX
OS   Synthetic.
XX
PN   WO2004016805-A2.
XX
PD   26-FEB-2004.
XX
PF   19-AUG-2003; 2003WO-US025935.
XX
PR   19-AUG-2002; 2002US-0404479P.
PR   19-AUG-2002; 2002US-0404820P.
PR   27-NOV-2002; 2002US-0429701P.
PR   14-FEB-2003; 2003US-0447377P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Samulowitz U,  Vollmer J,  Uhlmann E,  Jurk M,  Lipford G;
```

```
PI   Rankin R;
XX
DR   WPI; 2004-257200/24.
XX
PT   New immunostimulatory nucleic acid molecule having pyrimidine-purine
PT   dinucleotide and a chimeric backbone, useful in treating and preventing
PT   asthma, allergy, cancer, infectious disease, autoimmune disease or airway
PT   remodeling.
XX
PS   Example 10; SEQ ID NO 260; 276pp; English.
XX
CC   The invention relates to an immunostimulatory nucleic acid molecule
CC   comprising an internal pyrimidine-purine (YZ) dinucleotide and chimeric
CC   backbone, where one internal YZ dinucleotide has a phosphodiester(-like)
CC   internucleotide linkage, where optionally each additional internal YZ
CC   dinucleotide has a phosphodiester(-like) or stabilised internucleotide
CC   linkage, where other internucleotide linkages are stabilised. The
CC   oligonucleotide is useful in stimulating or modulating an immune
CC   response. The medicament shifts the immune response to a Th1 biased
CC   response from a Th2 biased response. The oligonucleotide is also useful
CC   in the manufacture of a medicament for treating asthma, allergy, cancer,
CC   infectious disease, autoimmune disease, airway remodeling or chronic
CC   obstructive pulmonary disease or in treating a subject who is a smoker or
CC   who is free of symptoms of asthma. The oligonucleotide is useful in
CC   inducing cytokine expression, e.g. IL-6 (interleukin-6), TNFalpha (tumour
CC   necrosis factor alpha), IFNalpha (interferon-alpha), IFNgamma (interferon
CC   -gamma) and IP-10 (interferon inducible protein). The oligonucleotide is
CC   also useful in treating and preventing infections caused by viruses,
CC   bacteria and parasites. The present sequence represents an
CC   immunostimulatory nucleic acid.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 3
ADK18990
ID   ADK18990 standard; DNA; 24 BP.
XX
AC   ADK18990;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Immunostimulatory nucleic acid #37.
XX
KW   immunostimulatory nucleic acid; asthma; allergy; cancer;
KW   infectious disease; autoimmune disease; airway remodeling;
KW   chronic obstructive pulmonary disease; asthma; IL-6; interleukin-6;
KW   TNFalpha; tumour necrosis factor alpha; IFNalpha; interferon-alpha;
KW   IFNgamma; interferon-gamma; IP-10; interferon inducible protein;
KW   viral infection; bacteria infection; parasitic infection; ss.
XX
OS   Synthetic.
XX
PN   WO2004016805-A2.
XX
PD   26-FEB-2004.
XX
PF   19-AUG-2003; 2003WO-US025935.
XX
PR   19-AUG-2002; 2002US-0404479P.
PR   19-AUG-2002; 2002US-0404820P.
PR   27-NOV-2002; 2002US-0429701P.
PR   14-FEB-2003; 2003US-0447377P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
PA   (COLE-) COLEY PHARM GMBH.
```

```
XX
PI   Krieg AM,  Samulowitz U,  Vollmer J,  Uhlmann E,  Jurk M,  Lipford G;
PI   Rankin R;
XX
DR   WPI; 2004-257200/24.
XX
PT   New immunostimulatory nucleic acid molecule having pyrimidine-purine
PT   dinucleotide and a chimeric backbone, useful in treating and preventing
PT   asthma, allergy, cancer, infectious disease, autoimmune disease or airway
PT   remodeling.
XX
PS   Claim 4; SEQ ID NO 37; 276pp; English.
XX
CC   The invention relates to an immunostimulatory nucleic acid molecule
CC   comprising an internal pyrimidine-purine (YZ) dinucleotide and chimeric
CC   backbone, where one internal YZ dinucleotide has a phosphodiester(-like)
CC   internucleotide linkage, where optionally each additional internal YZ
CC   dinucleotide has a phosphodiester(-like) or stabilised internucleotide
CC   linkage, where other internucleotide linkages are stabilised. The
CC   oligonucleotide is useful in stimulating or modulating an immune
CC   response. The medicament shifts the immune response to a Th1 biased
CC   response from a Th2 biased response. The oligonucleotide is also useful
CC   in the manufacture of a medicament for treating asthma, allergy, cancer,
CC   infectious disease, autoimmune disease, airway remodeling or chronic
CC   obstructive pulmonary disease or in treating a subject who is a smoker or
CC   who is free of symptoms of asthma. The oligonucleotide is useful in
CC   inducing cytokine expression, e.g. IL-6 (interleukin-6), TNFalpha (tumour
CC   necrosis factor alpha), IFNalpha (interferon-alpha), IFNgamma (interferon
CC   -gamma) and IP-10 (interferon inducible protein). The oligonucleotide is
CC   also useful in treating and preventing infections caused by viruses,
CC   bacteria and parasites. The present sequence represents an
CC   immunostimulatory nucleic acid.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 4
ADK19212
ID   ADK19212 standard; DNA; 24 BP.
XX
AC   ADK19212;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Immunostimulatory nucleic acid #258.
XX
KW   immunostimulatory nucleic acid; asthma; allergy; cancer;
KW   infectious disease; autoimmune disease; airway remodeling;
KW   chronic obstructive pulmonary disease; asthma; IL-6; interleukin-6;
KW   TNFalpha; tumour necrosis factor alpha; IFNalpha; interferon-alpha;
KW   IFNgamma; interferon-gamma; IP-10; interferon inducible protein;
KW   viral infection; bacteria infection; parasitic infection; ss.
XX
OS   Synthetic.
XX
PN   WO2004016805-A2.
XX
PD   26-FEB-2004.
XX
PF   19-AUG-2003; 2003WO-US025935.
XX
PR   19-AUG-2002; 2002US-0404479P.
PR   19-AUG-2002; 2002US-0404820P.
PR   27-NOV-2002; 2002US-0429701P.
PR   14-FEB-2003; 2003US-0447377P.
XX
```

```
PA   (COLE-) COLEY PHARM GROUP INC.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Samulowitz U,  Vollmer J,  Uhlmann E,  Jurk M,  Lipford G;
PI   Rankin R;
XX
DR   WPI; 2004-257200/24.
XX
PT   New immunostimulatory nucleic acid molecule having pyrimidine-purine
PT   dinucleotide and a chimeric backbone, useful in treating and preventing
PT   asthma, allergy, cancer, infectious disease, autoimmune disease or airway
PT   remodeling.
XX
PS   Example 10; SEQ ID NO 259; 276pp; English.
XX
CC   The invention relates to an immunostimulatory nucleic acid molecule
CC   comprising an internal pyrimidine-purine (YZ) dinucleotide and chimeric
CC   backbone, where one internal YZ dinucleotide has a phosphodiester(-like)
CC   internucleotide linkage, where optionally each additional internal YZ
CC   dinucleotide has a phosphodiester(-like) or stabilised internucleotide
CC   linkage, where other internucleotide linkages are stabilised. The
CC   oligonucleotide is useful in stimulating or modulating an immune
CC   response. The medicament shifts the immune response to a Th1 biased
CC   response from a Th2 biased response. The oligonucleotide is also useful
CC   in the manufacture of a medicament for treating asthma, allergy, cancer,
CC   infectious disease, autoimmune disease, airway remodeling or chronic
CC   obstructive pulmonary disease or in treating a subject who is a smoker or
CC   who is free of symptoms of asthma. The oligonucleotide is useful in
CC   inducing cytokine expression, e.g. IL-6 (interleukin-6), TNFalpha (tumour
CC   necrosis factor alpha), IFNalpha (interferon-alpha), IFNgamma (interferon
CC   -gamma) and IP-10 (interferon inducible protein). The oligonucleotide is
CC   also useful in treating and preventing infections caused by viruses,
CC   bacteria and parasites. The present sequence represents an
CC   immunostimulatory nucleic acid.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 5
ADO44306
ID   ADO44306 standard; DNA; 24 BP.
XX
AC   ADO44306;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Nucleotide sequence of a CpG ODN of class B.
XX
KW   HCV infection; CpG therapy; immunostimulatory; hepatotropic; virucide;
KW   gene therapy; ss.
XX
OS   Synthetic.
XX
PN   WO2004039829-A2.
XX
PD   13-MAY-2004.
XX
PF   29-OCT-2003; 2003WO-IB005520.
XX
PR   29-OCT-2002; 2002US-0421987P.
XX
PA   (COLE-) COLEY PHARM GROUP LTD.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Ahluwalia NK,  Efler SM,  Davis HL,  Vollmer J;
XX
```

```
DR   WPI; 2004-376156/35.
XX
PT   Treating a patient having hepatitis C virus (HCV) infection that was not
PT   successfully treated using a previous non-CpG therapy comprises
PT   administering to a subject a CpG immunostimulatory nucleic acid.
XX
PS   Example; SEQ ID NO 5; 89pp; English.
XX
CC   The invention relates to treating a patient having hepatitis C virus
CC   (HCV) infection that was not successfully treated using a previous non-
CC   CpG therapy. The method involves administering to a subject in need of
CC   such treatment a CpG immunostimulatory nucleic acid in an amount
CC   effective to treat the infection. In the treatment method, the non-CpG
CC   therapy includes interferon-alpha. The interferon-alpha is interferon-
CC   alpha-2b, interferon-alpha-2a or consensus interferon-alpha. The non-CpG
CC   therapy includes interferon-alpha or pegylated interferon-alpha and
CC   ribavirin. The CpG immunostimulatory nucleic acid is A, B or C class CpG
CC   immunostimulatory nucleic acid. The method further comprises
CC   administering interferon-alpha to the subject. The interferon-alpha is
CC   administered substantially simultaneously with the CpG immunostimulatory
CC   nucleic acid. The CpG immunostimulatoy nucleic acid comprises a backbone
CC   modification, preferably a phosphorothionate backbone modification. The
CC   CpG immunostimulatory nucleic acid comprises a semi-soft backbone. The
CC   method is useful for treating a patient having hepatitis C virus (HCV)
CC   infection that was not successfully treated using a previous non-CpG
CC   therapy. Sequences ADO44302-ADO44317 represent examples of CpG
CC   oligodeoxynucleotides (ODN) which were used in the experiments to
CC   exemplify the methods of the invention.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 6
ADT04268
ID   ADT04268 standard; DNA; 24 BP.
XX
AC   ADT04268;
XX
DT   30-DEC-2004  (first entry)
XX
DE   Novel immunostimulatory oligonucleotide sequence SeqID150.
XX
KW   immune response; oil-in-water emulsion; immunostimulatory nucleic acid;
KW   cytostatic; antibacterial; virucide; fungicide; antiparasitic;
KW   dermatological; antipsoriatic; antiallergic; antimalarial; hepatotropic;
KW   antiinflammatory; immunosuppressive; antiasthmatic; gastrointestinal-Gen;
KW   antiulcer; infectious disease; bacterial infection; fungal infection;
KW   viral infection; melanoma; basal cell carcinoma; cervical cancer;
KW   contact dermatitis; eczema; psoriasis; atopic dermatitis;
KW   allergic contact dermatitis; latex dermatitis; oesophageal cancer;
KW   eye cancer; larynx cancer; oral cavity cancer; skin cancer;
KW   ovarian cancer; testicular cancer; parasitic infection; malaria;
KW   anaphylaxis; allergic rhinitis; allergic asthma;
KW   inflammatory bowel disease; Crohn's disease; ulcerative colitis; ss.
XX
OS   Unidentified.
OS   Synthetic.
XX
PN   WO2004087203-A2.
XX
PD   14-OCT-2004.
XX
PF   01-APR-2004; 2004WO-IB001371.
XX
PR   02-APR-2003; 2003US-0459920P.
PR   10-APR-2003; 2003US-0461903P.
```

XX
PA (COLE-) COLEY PHARM GROUP LTD.
XX
PI Davis HL, Mccluskie MJ;
XX
DR WPI; 2004-737575/72.
XX
PT Inducing immune response in subject useful for preventing and/or treating
PT viral infection e.g., human papilloma virus infection, involves topically
PT administering oil-in-water emulsion and immunostimulatory nucleic acid,
PT to subject.
XX
PS Claim 27; SEQ ID NO 150; 188pp; English.
XX
CC This invention relates to a novel method of inducing an immune response,
CC which involves topically administering to a subject an oil-in-water
CC emulsion and an immunostimulatory nucleic acid to induce an immune
CC response. The invention may be useful for the production of compounds
CC with a cytostatic, antibacterial, virucide, fungicide, antiparasitic,
CC dermatological, antipsoriatic, antiallergic, antimalarial, hepatotropic,
CC antiinflammatory, immunosuppressive, antiasthmatic, gastrointestinal-Gen
CC or antiulcer activity. The method is useful for inducing an immune
CC response in a subject having cancer or an infectious disease, or at risk
CC of developing an infectious disease such as bacterial infection, fungal
CC infection or viral infection, where the subject is an immunocompromised
CC subject. The cancer is chosen from melanoma, basal cell carcinoma and
CC cervical cancer. The subject has or is at risk of developing a condition
CC chosen from contact dermatitis, eczema, psoriasis, atopic dermatitis,
CC allergic contact dermatitis and latex dermatitis. The oil-in-water
CC emulsion and immunostimulatory nucleic acid of the invention is useful
CC for treating a subject having oesophageal cancer, eye cancer, larynx
CC cancer, oral cavity cancer, skin cancer, ovarian cancer and testicular
CC cancer, parasitic infection caused by parasites such as Leishmania
CC donovani, or Plasmodium falciparum, P malariae or P vivax causing
CC malaria, infection caused by Staphylococcus or Escherichia coli
CC infection, or viral infections caused by Hepatitis B virus or Hepatitis C
CC virus. The invention is useful in treating anaphylaxis, allergic rhinitis
CC or allergic asthma, inflammatory bowel disease, Crohn's disease and
CC ulcerative colitis. The invention is also useful for stimulating immune
CC responses, useful in the prevention and/or treatment of the above-
CC mentioned diseases. The oil-in-water emulsion and the immunostimulatory
CC nucleic acid of the invention is capable of inducing long lasting antigen
CC -specific responses. The present sequence is that of an immunostimulatory
CC oligonucleotide which may be used in the method of the invention.
XX
SQ Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

Query Match 100.0%; Score 24; DB 13; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
```

RESULT 7
ADT04343
ID ADT04343 standard; DNA; 24 BP.
XX
AC ADT04343;
XX
DT 30-DEC-2004 (first entry)
XX
DE Novel immunostimulatory oligonucleotide sequence SeqID225.
XX
KW immune response; oil-in-water emulsion; immunostimulatory nucleic acid;
KW cytostatic; antibacterial; virucide; fungicide; antiparasitic;
KW dermatological; antipsoriatic; antiallergic; antimalarial; hepatotropic;
KW antiinflammatory; immunosuppressive; antiasthmatic; gastrointestinal-Gen;
KW antiulcer; infectious disease; bacterial infection; fungal infection;
KW viral infection; melanoma; basal cell carcinoma; cervical cancer;
KW contact dermatitis; eczema; psoriasis; atopic dermatitis;
KW allergic contact dermatitis; latex dermatitis; oesophageal cancer;

```
KW   eye cancer; larynx cancer; oral cavity cancer; skin cancer;
KW   ovarian cancer; testicular cancer; parasitic infection; malaria;
KW   anaphylaxis; allergic rhinitis; allergic asthma;
KW   inflammatory bowel disease; Crohn's disease; ulcerative colitis; ss.
XX
OS   Unidentified.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .2
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   3. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   6. .10
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   11. .13
FT                   /*tag=  d
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   14. .21
FT                   /*tag=  e
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   22. .24
FT                   /*tag=  f
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
XX
PN   WO2004087203-A2.
XX
PD   14-OCT-2004.
XX
PF   01-APR-2004; 2004WO-IB001371.
XX
PR   02-APR-2003; 2003US-0459920P.
PR   10-APR-2003; 2003US-0461903P.
XX
PA   (COLE-) COLEY PHARM GROUP LTD.
XX
PI   Davis HL,  Mccluskie MJ;
XX
DR   WPI; 2004-737575/72.
XX
PT   Inducing immune response in subject useful for preventing and/or treating
PT   viral infection e.g., human papilloma virus infection, involves topically
PT   administering oil-in-water emulsion and immunostimulatory nucleic acid,
PT   to subject.
XX
PS   Disclosure; SEQ ID NO 225; 188pp; English.
XX
CC   This invention relates to a novel method of inducing an immune response,
CC   which involves topically administering to a subject an oil-in-water
CC   emulsion and an immunostimulatory nucleic acid to induce an immune
CC   response. The invention may be useful for the production of compounds
CC   with a cytostatic, antibacterial, virucide, fungicide, antiparasitic,
CC   dermatological, antipsoriatic, antiallergic, antimalarial, hepatotropic,
CC   antiinflammatory, immunosuppressive, antiasthmatic, gastrointestinal-Gen
CC   or antiulcer activity. The method is useful for inducing an immune
CC   response in a subject having cancer or an infectious disease, or at risk
CC   of developing an infectious disease such as bacterial infection, fungal
CC   infection or viral infection, where the subject is an immunocompromised
CC   subject. The cancer is chosen from melanoma, basal cell carcinoma and
CC   cervical cancer. The subject has or is at risk of developing a condition
CC   chosen from contact dermatitis, eczema, psoriasis, atopic dermatitis,
CC   allergic contact dermatitis and latex dermatitis. The oil-in-water
CC   emulsion and immunostimulatory nucleic acid of the invention is useful
CC   for treating a subject having oesophageal cancer, eye cancer, larynx
CC   cancer, oral cavity cancer, skin cancer, ovarian cancer and testicular
```

```
CC   cancer, parasitic infection caused by parasites such as Leishmania
CC   donovani, or Plasmodium falciparum, P malariae or P vivax causing
CC   malaria, infection caused by Staphylococcus or Escherichia coli
CC   infection, or viral infections caused by Hepatitis B virus or Hepatitis C
CC   virus. The invention is useful in treating anaphylaxis, allergic rhinitis
CC   or allergic asthma, inflammatory bowel disease, Crohn's disease and
CC   ulcerative colitis. The invention is also useful for stimulating immune
CC   responses, useful in the prevention and/or treatment of the above-
CC   mentioned diseases. The oil-in-water emulsion and the immunostimulatory
CC   nucleic acid of the invention is capable of inducing long lasting antigen
CC   -specific responses. The present sequence is that of an immunostimulatory
CC   oligonucleotide which may be used in the method of the invention.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 13;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 8
ADU23248
ID   ADU23248 standard; DNA; 24 BP.
XX
AC   ADU23248;
XX
DT   27-JAN-2005  (first entry)
XX
DE   Toll-like receptor 9 (TLR9) ligand oligonucleotide - SEQ ID 142.
XX
KW   screening; Toll-like receptor agonist; TLR agonist;
KW   Toll-like receptor 9 ligand; TLR9 ligand; ss.
XX
OS   Unidentified.
XX
PN   WO2004094671-A2.
XX
PD   04-NOV-2004.
XX
PF   22-APR-2004; 2004WO-US012788.
XX
PR   22-APR-2003; 2003US-0464586P.
PR   22-APR-2003; 2003US-0464588P.
XX
PA   (COLE-) COLEY PHARM GMBH.
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Vollmer J,  Jurk M,  Lipford GB,  Schetter C,  Forsbach A,  Krieg AM;
XX
DR   WPI; 2004-795573/78.
XX
PT   Identifying agonists of Toll-like receptor (TLR) signaling activity,
PT   useful therapeutically or prophylactically, comprises contacting an
PT   RPMI8226 cell that expresses a TLR with a test compound and measuring TLR
PT   signaling activity.
XX
PS   Claim 166; SEQ ID NO 142; 342pp; English.
XX
CC   The invention comprises a screening method for identifying agonists of
CC   Toll-like receptor (TLR) signalling activity. The method involves
CC   contacting an RPMI8226 cell (that expresses a TLR) with a test compound,
CC   and measuring a test level of TLR signalling activity, where a test level
CC   that is positive is indicative of a test compound that is a TLR agonist.
CC   The method of the invention is useful for identifying agonists of TLR.
CC   The present DNA sequence represents a TLR9 ligand of the invention.
XX
SQ   Sequence 24 BP; 0 A; 5 C; 6 G; 13 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 13;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
```

```
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 9
ABQ18805/c
ID   ABQ18805 standard; DNA; 578 BP.
XX
AC   ABQ18805;
XX
DT   12-JUL-2002  (first entry)
XX
DE   Oligonucleotide for detecting cytosine methylation SEQ ID NO 5396.
XX
KW   Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW   drug; side effect; cancer; central nervous system; cardiovascular;
KW   gastrointestinal; respiratory system; single nucleotide polymorphism;
KW   SNP; cell differentiation; ds.
XX
OS   Homo sapiens.
XX
PN   WO200218632-A2.
XX
PD   07-MAR-2002.
XX
PF   01-SEP-2001; 2001WO-EP010074.
XX
PR   01-SEP-2000; 2000DE-01043826.
PR   05-SEP-2000; 2000DE-01044543.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K,  Guetig D;
XX
DR   WPI; 2002-371829/40.
XX
PT   Determining the degree of cytosine methylation in genomic DNA, useful for
PT   diagnosis and prognosis, comprises selective hybridization of amplicons
PT   from chemically treated DNA.
XX
PS   Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
CC   This invention describes a novel method for determining the degree of
CC   methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC   genomic sample of DNA. The sample is treated chemically to convert
CC   cytosine (C) but not methylated C, to uracil, then part of the genomic
CC   DNA that contains the target C is amplified to form a labeled amplicon.
CC   The amplicon is hybridised to two classes, each with at least one member,
CC   of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC   degree of hybridisation to both classes is determined from the label on
CC   the amplicon. From the ratio of labels hybridised to the two classes of
CC   oligomers, the degree of methylation is calculated. The method is used:
CC   (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC   and of a wide range of diseases, e.g. cancer, disorders of the central
CC   nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC   particularly by detecting mutations or single nucleotide polymorphisms
CC   (SNP's); and (ii) for differentiation of cell or tissue types and for
CC   investigating cell differentiation. The method allows the methylation
CC   status of many C residues to be determined simultaneously. ABQ13410-
CC   ABQ54121 represent genomic DNA sequences used to illustrate the method
CC   for determining the degree of cytosine methylation described in the
CC   disclosure of the invention
XX
SQ   Sequence 578 BP; 337 A; 110 C; 97 G; 23 T; 0 U; 11 Other;

  Query Match             100.0%;  Score 24;  DB 6;  Length 578;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
```

Not Valid under 102(e) Post AIPA

```
Db         93 TCGTCGTTTCGTCGTTTTGTCGTT 70


RESULT 10
ABQ18804
ID   ABQ18804 standard; DNA; 578 BP.
XX
AC   ABQ18804;
XX
DT   12-JUL-2002  (first entry)
XX
DE   Oligonucleotide for detecting cytosine methylation SEQ ID NO:5395.
XX
KW   Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW   drug; side effect; cancer; central nervous system; cardiovascular;
KW   gastrointestinal; respiratory system; single nucleotide polymorphism;
KW   SNP; cell differentiation; ds.
XX
OS   Homo sapiens.
XX
PN   WO200218632-A2.
XX
PD   07-MAR-2002.
XX
PF   01-SEP-2001; 2001WO-EP010074.
XX
PR   01-SEP-2000; 2000DE-01043826.
PR   05-SEP-2000; 2000DE-01044543.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K,  Guetig D;
XX
DR   WPI; 2002-371829/40.
XX
PT   Determining the degree of cytosine methylation in genomic DNA, useful for
PT   diagnosis and prognosis, comprises selective hybridization of amplicons
PT   from chemically treated DNA.
XX
PS   Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
CC   This invention describes a novel method for determining the degree of
CC   methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC   genomic sample of DNA. The sample is treated chemically to convert
CC   cytosine (C) but not methylated C, to uracil, then part of the genomic
CC   DNA that contains the target C is amplified to form a labeled amplicon.
CC   The amplicon is hybridised to two classes, each with at least one member,
CC   of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC   degree of hybridisation to both classes is determined from the label on
CC   the amplicon. From the ratio of labels hybridised to the two classes of
CC   oligomers, the degree of methylation is calculated. The method is used:
CC   (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC   and of a wide range of diseases, e.g. cancer, disorders of the central
CC   nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC   particularly by detecting mutations or single nucleotide polymorphisms
CC   (SNP's); and (ii) for differentiation of cell or tissue types and for
CC   investigating cell differentiation. The method allows the methylation
CC   status of many C residues to be determined simultaneously. ABQ13410-
CC   ABQ54121 represent genomic DNA sequences used to illustrate the method
CC   for determining the degree of cytosine methylation described in the
CC   disclosure of the invention
XX
SQ   Sequence 578 BP; 23 A; 97 C; 110 G; 337 T; 0 U; 11 Other;

  Query Match             100.0%;  Score 24;  DB 6;  Length 578;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db        486 TCGTCGTTTCGTCGTTTTGTCGTT 509


RESULT 11
```

```
ABQ18198
ID   ABQ18198 standard; DNA; 619 BP.
XX
AC   ABQ18198;
XX
DT   12-JUL-2002  (first entry)
XX
DE   Oligonucleotide for detecting cytosine methylation SEQ ID NO 4789.
XX
KW   Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW   drug; side effect; cancer; central nervous system; cardiovascular;
KW   gastrointestinal; respiratory system; single nucleotide polymorphism;
KW   SNP; cell differentiation; ds.
XX
OS   Homo sapiens.
XX
PN   WO200218632-A2.
XX
PD   07-MAR-2002.
XX
PF   01-SEP-2001; 2001WO-EP010074.
XX
PR   01-SEP-2000; 2000DE-01043826.
PR   05-SEP-2000; 2000DE-01044543.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K,  Guetig D;
XX
DR   WPI; 2002-371829/40.
XX
PT   Determining the degree of cytosine methylation in genomic DNA, useful for
PT   diagnosis and prognosis, comprises selective hybridization of amplicons
PT   from chemically treated DNA.
XX
PS   Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
CC   This invention describes a novel method for determining the degree of
CC   methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC   genomic sample of DNA. The sample is treated chemically to convert
CC   cytosine (C) but not methylated C, to uracil, then part of the genomic
CC   DNA that contains the target C is amplified to form a labeled amplicon.
CC   The amplicon is hybridised to two classes, each with at least one member,
CC   of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC   degree of hybridisation to both classes is determined from the label on
CC   the amplicon. From the ratio of labels hybridised to the two classes of
CC   oligomers, the degree of methylation is calculated. The method is used:
CC   (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC   and of a wide range of diseases, e.g. cancer, disorders of the central
CC   nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC   particularly by detecting mutations or single nucleotide polymorphisms
CC   (SNP's); and (ii) for differentiation of cell or tissue types and for
CC   investigating cell differentiation. The method allows the methylation
CC   status of many C residues to be determined simultaneously. ABQ13410-
CC   ABQ54121 represent genomic DNA sequences used to illustrate the method
CC   for determining the degree of cytosine methylation described in the
CC   disclosure of the invention
XX
SQ   Sequence 619 BP; 69 A; 66 C; 167 G; 317 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 6;  Length 619;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db        352 TCGTCGTTTCGTCGTTTTGTCGTT 375


RESULT 12
ABQ18199/c
ID   ABQ18199 standard; DNA; 619 BP.
XX
AC   ABQ18199;
```

```
XX
DT   12-JUL-2002  (first entry)
XX
DE   Oligonucleotide for detecting cytosine methylation SEQ ID NO 4790.
XX
KW   Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW   drug; side effect; cancer; central nervous system; cardiovascular;
KW   gastrointestinal; respiratory system; single nucleotide polymorphism;
KW   SNP; cell differentiation; ds.
XX
OS   Homo sapiens.
XX
PN   WO200218632-A2.
XX
PD   07-MAR-2002.
XX
PF   01-SEP-2001; 2001WO-EP010074.
XX
PR   01-SEP-2000; 2000DE-01043826.
PR   05-SEP-2000; 2000DE-01044543.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K,  Guetig D;
XX
DR   WPI; 2002-371829/40.
XX
PT   Determining the degree of cytosine methylation in genomic DNA, useful for
PT   diagnosis and prognosis, comprises selective hybridization of amplicons
PT   from chemically treated DNA.
XX
PS   Claim 12; 56pp + Sequence Listing; 56pp; German.
XX
CC   This invention describes a novel method for determining the degree of
CC   methylation of a particular cytosine in a motif 5'-CpG-3', present in a
CC   genomic sample of DNA. The sample is treated chemically to convert
CC   cytosine (C) but not methylated C, to uracil, then part of the genomic
CC   DNA that contains the target C is amplified to form a labeled amplicon.
CC   The amplicon is hybridised to two classes, each with at least one member,
CC   of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
CC   degree of hybridisation to both classes is determined from the label on
CC   the amplicon. From the ratio of labels hybridised to the two classes of
CC   oligomers, the degree of methylation is calculated. The method is used:
CC   (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
CC   and of a wide range of diseases, e.g. cancer, disorders of the central
CC   nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
CC   particularly by detecting mutations or single nucleotide polymorphisms
CC   (SNP's); and (ii) for differentiation of cell or tissue types and for
CC   investigating cell differentiation. The method allows the methylation
CC   status of many C residues to be determined simultaneously. ABQ13410-
CC   ABQ54121 represent genomic DNA sequences used to illustrate the method
CC   for determining the degree of cytosine methylation described in the
CC   disclosure of the invention
XX
SQ   Sequence 619 BP; 317 A; 167 C; 66 G; 69 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 6;  Length 619;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db        268 TCGTCGTTTCGTCGTTTTGTCGTT 245


RESULT 13
ADP84798
ID   ADP84798 standard; DNA; 10160 BP.
XX
AC   ADP84798;
XX
DT   23-SEP-2004  (first entry)
XX
DE   HIV subtype B vaccine DNA.
```

```
XX
KW   eliciting; inducing; immune response; HIV; antigen; non-pathogenic;
KW   vaccination; vaccine; HIV-I; ds.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO2004056391-A1.
XX
PD   08-JUL-2004.
XX
PF   19-DEC-2003; 2003WO-AU001705.
XX
PR   20-DEC-2002; 2002AU-00953556.
PR   17-SEP-2003; 2003AU-00905067.
XX
PA   (UYNE-) UNIV NEW SOUTH WALES.
XX
PI   Kent SJ,  Purcell DF,  Boyle DB,  Ramsay A,  Thomson S,  Ramshaw IA;
XX
DR   WPI; 2004-500267/47.
XX
PT   Eliciting or inducing in a mammal an immune response against HIV-I
PT   subtype AE, B or C by administering sequential doses of a recombinant
PT   plasmid and viral vectors containing the nucleic acid molecules encoding
PT   the HIV antigens.
XX
PS   Claim 69; SEQ ID NO 3; 280pp; English.
XX
CC   The invention relates to a novel method for eliciting or inducing in a
CC   mammal an immune response directed to a virus, preferably Human
CC   immunodeficiency virus (HIV). The method comprises sequentially
CC   administering to the mammal one or more sequential doses of a recombinant
CC   plasmid vector or recombinant viral vector or its derivative, into which
CC   the nucleic acid molecules encoding all, part or a modified form of two
CC   or more antigens of the virus are incorporated, and one or more optimized
CC   CpG motifs, where the antigens have been rendered substantially non-
CC   pathogenic. The invention further comprises: a method for treating or
CC   preventing viral infection in a mammal; a method of vaccinating a mammal
CC   against a viral pathogen; a method of eliciting or inducing, in a mammal,
CC   an immune response directed to HIV; a vaccine capable of inducing an
CC   immune response directed to a virus comprising the recombinant plasmid
CC   vector or recombinant viral vector or its functional derivative; a
CC   nucleic acid construct or its functional derivative comprising the
CC   plasmid vector or recombinant viral vector; a plasmid vector; a
CC   recombinant viral vector; a pharmaceutical composition comprising the
CC   nucleic acid, plasmid vector or recombinant viral vector constructs. The
CC   method is useful in eliciting or inducing in a mammal an immune response
CC   against HIV-I subtype AE, B or C. This polynucleotide represents the DNA
CC   of a HIV subtype B vaccine sequence of the invention.
XX
SQ   Sequence 10160 BP; 3150 A; 2051 C; 2469 G; 2490 T; 0 U; 0 Other;

  Query Match             100.0%;  Score 24;  DB 12;  Length 10160;
  Best Local Similarity   100.0%;  Pred. No. 1.2;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db       8917 TCGTCGTTTCGTCGTTTTGTCGTT 8940


RESULT 14
ADI16184
ID   ADI16184 standard; DNA; 23 BP.
XX
AC   ADI16184;
XX
DT   22-APR-2004  (first entry)
XX
DE   Immunostimulatory oligodeoxynucleotide SEQ ID NO:115.
XX
KW   ds; immunostimulatory; antibacterial; antiallergic; antiasthmatic;
KW   cytostatic; virucide; fungicide; antiparasitic; interleukin antagonist;
KW   gene therapy; infectious disease; allergy; asthma; cancer.
```

XX
OS Unidentified.
XX
PN WO2004005476-A2.
XX
PD 15-JAN-2004.
XX
PF 03-JUL-2003; 2003WO-US021113.
XX
PR 03-JUL-2002; 2002US-0393880P.
PR 03-JUL-2002; 2002US-0394090P.
PR 03-JUL-2002; 2002US-0394091P.
PR 03-JUL-2002; 2002US-0394164P.
PR 03-JUL-2002; 2002US-0394193P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Krieg AM;
XX
DR WPI; 2004-091353/09.
XX
PT New immunostimulatory nucleic acid molecule composition comprising CpG
PT motifs, useful for diagnosing, preventing and/or treating infectious
PT diseases, allergies, asthma and cancers.
XX
PS Disclosure; SEQ ID NO 115; 257pp; English.
XX
CC The invention relates to a novel composition comprising an
CC immunostimulatory nucleic acid molecule. A composition of the invention
CC has antibacterial, antiallergic, antiasthmatic, cytostatic, virucide,
CC fungicide, and antiparasitic activity. A composition may act as an
CC interleukin antagonist-4, or interleukin antagonist-5, and may have a use
CC in gene therapy. The methods and compositions of the present invention
CC are useful for diagnosing, preventing and/or treating infectious disease,
CC allergy, asthma, cancer, where the infectious disease is a herpes simplex
CC virus, bacterial, fungal or parasitic infection, and where the cancer is
CC a biliary tract cancer, bone cancer, brain and CNS cancer, breast cancer,
CC cervical cancer, choriocarcinoma, colon cancer, connective tissue cancer,
CC endometrial cancer, oesophageal cancer, eye cancer, gastric cancer,
CC Hodgkin's lymphoma, intraepithelial neoplasms, larynx cancer, lymphomas,
CC liver cancer, lung cancer (e.g. small cell and non-small cell), melanoma,
CC neuroblastomas, oral cavity cancer, ovarian cancer, pancreas cancer,
CC prostate cancer, rectal cancer, sarcomas, skin cancer, testicular cancer,
CC thyroid cancer and renal cancer. The present sequence represents an
CC immunostimulatory nucleic acid molecule of the invention.
XX
SQ Sequence 23 BP; 0 A; 5 C; 6 G; 12 T; 0 U; 0 Other;

Query Match 95.8%; Score 23; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 TCGTCGTTTCGTCGTTTTGTCGT 23
              |||||||||||||||||||||||
Db          1 TCGTCGTTTCGTCGTTTTGTCGT 23
```

RESULT 15
ADI16179
ID ADI16179 standard; DNA; 23 BP.
XX
AC ADI16179;
XX
DT 22-APR-2004 (first entry)
XX
DE Immunostimulatory oligodeoxynucleotide SEQ ID NO:110.
XX
KW ds; immunostimulatory; antibacterial; antiallergic; antiasthmatic;
KW cytostatic; virucide; fungicide; antiparasitic; interleukin antagonist;
KW gene therapy; infectious disease; allergy; asthma; cancer.
XX
OS Unidentified.
XX
PN WO2004005476-A2.

XX
PD 15-JAN-2004.
XX
PF 03-JUL-2003; 2003WO-US021113.
XX
PR 03-JUL-2002; 2002US-0393880P.
PR 03-JUL-2002; 2002US-0394090P.
PR 03-JUL-2002; 2002US-0394091P.
PR 03-JUL-2002; 2002US-0394164P.
PR 03-JUL-2002; 2002US-0394193P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Krieg AM;
XX
DR WPI; 2004-091353/09.
XX
PT New immunostimulatory nucleic acid molecule composition comprising CpG
PT motifs, useful for diagnosing, preventing and/or treating infectious
PT diseases, allergies, asthma and cancers.
XX
PS Disclosure; SEQ ID NO 110; 257pp; English.
XX
CC The invention relates to a novel composition comprising an
CC immunostimulatory nucleic acid molecule. A composition of the invention
CC has antibacterial, antiallergic, antiasthmatic, cytostatic, virucide,
CC fungicide, and antiparasitic activity. A composition may act as an
CC interleukin antagonist-4, or interleukin antagonist-5, and may have a use
CC in gene therapy. The methods and compositions of the present invention
CC are useful for diagnosing, preventing and/or treating infectious disease,
CC allergy, asthma, cancer, where the infectious disease is a herpes simplex
CC virus, bacterial, fungal or parasitic infection, and where the cancer is
CC a biliary tract cancer, bone cancer, brain and CNS cancer, breast cancer,
CC cervical cancer, choriocarcinoma, colon cancer, connective tissue cancer,
CC endometrial cancer, oesophageal cancer, eye cancer, gastric cancer,
CC Hodgkin's lymphoma, intraepithelial neoplasms, larynx cancer, lymphomas,
CC liver cancer, lung cancer (e.g. small cell and non-small cell), melanoma,
CC neuroblastomas, oral cavity cancer, ovarian cancer, pancreas cancer,
CC prostate cancer, rectal cancer, sarcomas, skin cancer, testicular cancer,
CC thyroid cancer and renal cancer. The present sequence represents an
CC immunostimulatory nucleic acid molecule of the invention.
XX
SQ Sequence 23 BP; 0 A; 5 C; 6 G; 12 T; 0 U; 0 Other;

Query Match 95.8%; Score 23; DB 12; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.5;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          2 CGTCGTTTCGTCGTTTTGTCGTT 24
              |||||||||||||||||||||||
Db          1 CGTCGTTTCGTCGTTTTGTCGTT 23
```

Search completed: December 31, 2005, 00:45:09
Job time : 270 secs

SCORE 1.3 BuildDate: 12/06/2005

SCORE Search Results Details for Application 10613739 and Search Result us-10-613-739-1.rge.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10613739 and Search Result us-10-613-739-1.rge.

start

Go Back to previous page

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 31, 2005, 00:29:05 ; Search time 1720 Seconds
(without alignments)
793.164 Million cell updates/sec

Title: US-10-613-739-1
Perfect score: 24
Sequence: 1 tcgtcgtttcgtcgttttgtcgtt 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 5883141 seqs, 28421725653 residues

Total number of hits satisfying chosen parameters: 11766282

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: gb_ba:*
2: gb_in:*
3: gb_env:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pr:*
9: gb_ro:*
10: gb_sts:*
11: gb_sy:*
12: gb_un:*
13: gb_vi:*
14: gb_htg:*
15: gb_pl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	24	100.0	24	6	CQ892107	CQ892107 Sequence
2	24	100.0	24	6	CQ892182	CQ892182 Sequence
3	24	100.0	24	6	CQ903956	CQ903956 Sequence
4	23	95.8	24	6	CQ892206	CQ892206 Sequence
5	22.4	93.3	24	6	AR146378	AR146378 Sequence

6	22.4	93.3	24	6	AR154717	AR154717 Sequence
7	22.4	93.3	24	6	BD069917	BD069917 Use of nu
8	22.4	93.3	24	6	BD205600	BD205600 Method of
9	22.4	93.3	24	6	BD261142	BD261142 Methods a
10	22.4	93.3	24	6	BD261298	BD261298 Methods a
11	22.4	93.3	24	6	BD261563	BD261563 Vaccine.
12	22.4	93.3	24	6	BD267904	BD267904 Methods f
13	22.4	93.3	24	6	BD270804	BD270804 Stereoiso
14	22.4	93.3	24	6	CQ769070	CQ769070 Sequence
15	22.4	93.3	24	6	CQ788116	CQ788116 Sequence
16	22.4	93.3	24	6	CQ788202	CQ788202 Sequence
17	22.4	93.3	24	6	CQ815138	CQ815138 Sequence
18	22.4	93.3	24	6	CQ875565	CQ875565 Sequence
19	22.4	93.3	24	6	CQ892034	CQ892034 Sequence
20	22.4	93.3	24	6	CQ892104	CQ892104 Sequence
21	22.4	93.3	24	6	CQ892105	CQ892105 Sequence
22	22.4	93.3	24	6	CQ892175	CQ892175 Sequence
23	22.4	93.3	24	6	CQ892181	CQ892181 Sequence
24	22.4	93.3	24	6	CQ892202	CQ892202 Sequence
25	22.4	93.3	24	6	CQ892204	CQ892204 Sequence
26	22.4	93.3	24	6	CQ892250	CQ892250 Sequence
27	22.4	93.3	24	6	CQ892251	CQ892251 Sequence
28	22.4	93.3	24	6	CQ892252	CQ892252 Sequence
29	22.4	93.3	24	6	CQ892253	CQ892253 Sequence
30	22.4	93.3	24	6	CQ892254	CQ892254 Sequence
31	22.4	93.3	24	6	CQ892255	CQ892255 Sequence
32	22.4	93.3	24	6	CQ892256	CQ892256 Sequence
33	22.4	93.3	24	6	CQ892257	CQ892257 Sequence
34	22.4	93.3	24	6	CQ892258	CQ892258 Sequence
35	22.4	93.3	24	6	CQ892259	CQ892259 Sequence
36	22.4	93.3	24	6	CQ892260	CQ892260 Sequence
37	22.4	93.3	24	6	CQ892261	CQ892261 Sequence
38	22.4	93.3	24	6	CQ892262	CQ892262 Sequence
39	22.4	93.3	24	6	CQ892263	CQ892263 Sequence
40	22.4	93.3	24	6	CQ892264	CQ892264 Sequence
41	22.4	93.3	24	6	CQ892265	CQ892265 Sequence
42	22.4	93.3	24	6	CQ892266	CQ892266 Sequence
43	22.4	93.3	24	6	CQ892267	CQ892267 Sequence
44	22.4	93.3	24	6	CQ892268	CQ892268 Sequence
45	22.4	93.3	24	6	CQ892269	CQ892269 Sequence

ALIGNMENTS

```
RESULT 1
CQ892107
LOCUS       CQ892107                  24 bp    DNA     linear   PAT 01-NOV-2004
DEFINITION  Sequence 150 from Patent WO2004087203.
ACCESSION   CQ892107
VERSION     CQ892107.1  GI:55164665
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Davis,H.L. and Mccluskie,M.J.
  TITLE     Immunostimulatory nucleic acid oil-in-water formulations and
            related methods of use
  JOURNAL   Patent: WO 2004087203-A 150 14-OCT-2004;
            Coley Pharmaceutical Group, Ltd. (CA)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide"
ORIGIN

  Query Match             100.0%;  Score 24;  DB 6;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 3.6;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
```

```
              ||||||||||||||||||||||||
Db            1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 2
CQ892182
LOCUS       CQ892182                 24 bp    DNA     linear   PAT 01-NOV-2004
DEFINITION  Sequence 225 from Patent WO2004087203.
ACCESSION   CQ892182
VERSION     CQ892182.1  GI:55164740
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Davis,H.L. and Mccluskie,M.J.
  TITLE     Immunostimulatory nucleic acid oil-in-water formulations and
            related methods of use
  JOURNAL   Patent: WO 2004087203-A 225 14-OCT-2004;
            Coley Pharmaceutical Group, Ltd. (CA)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide"
ORIGIN

  Query Match             100.0%;  Score 24;  DB 6;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 3.6;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy            1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db            1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 3
CQ903956
LOCUS       CQ903956                 24 bp    DNA     linear   PAT 16-NOV-2004
DEFINITION  Sequence 142 from Patent WO2004094671.
ACCESSION   CQ903956
VERSION     CQ903956.1  GI:55785348
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Vollmer,J., Jurk,M., Lipford,G.B., Schetter,C., Forsbach,A. and
            Krieg,A.M.
  TITLE     Methods and products for identification and assessment of tlr
            ligands
  JOURNAL   Patent: WO 2004094671-A 142 04-NOV-2004;
            Coley Pharmaceutical GmbH (DE); Coley Pharmaceutical Group, Inc.
            (US)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Immunostimulatory nucleic acid"
ORIGIN

  Query Match             100.0%;  Score 24;  DB 6;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 3.6;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy            1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||||||||||||||||||
Db            1 TCGTCGTTTCGTCGTTTTGTCGTT 24


RESULT 4
CQ892206
```

SCORE Search Results Details for Application 10613739 and Search Result us-10-613-739-1.rst.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10613739 and Search Result us-10-613-739-1.rst.

start

Go Back to previous page

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: December 31, 2005, 00:37:55 ; Search time 1908 Seconds
(without alignments)
588.517 Million cell updates/sec

Title: US-10-613-739-1
Perfect score: 24
Sequence: 1 tcgtcgtttcgtcgttttgtcgtt 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 41078325 seqs, 23393541228 residues

Total number of hits satisfying chosen parameters: 82156650

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*
1: gb_est1:*
2: gb_est2:*
3: gb_est3:*
4: gb_htc:*
5: gb_est4:*
6: gb_est5:*
7: gb_est6:*
8: gb_est7:*
9: gb_gss1:*
10: gb_gss2:*
11: gb_gss3:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		21.4	89.2	850	9	AZ183817	AZ183817 SP_1002_A
2		20.8	86.7	330	7	CO902262	CO902262 Mdfrt3057
3		20.8	86.7	472	7	CN492399	CN492399 Mdfw20131
4	C	20.8	86.7	523	2	BG789225	BG789225 SEAUMC009
5		20.8	86.7	550	7	CO752082	CO752082 Mdfrt3053
6		20.8	86.7	603	7	CN489009	CN489009 Mdfw2018k
7	C	19.8	82.5	463	2	BG789245	BG789245 SEAUMC009
8	C	19.8	82.5	663	9	BZ043048	BZ043048 1ki56g02.
9		19.8	82.5	785	9	BH543978	BH543978 BOGYN73TF
10	C	19.8	82.5	832	9	CC132027	CC132027 NDL.23F6.

	11	19.2	80.0	292	7	CN497106	CN497106 Mdfw2023n
c	12	19.2	80.0	366	1	AU286121	AU286121 AU286121
	13	19.2	80.0	367	1	AU287428	AU287428 AU287428
	14	19.2	80.0	490	10	CZ245807	CZ245807 AIAA-aag1
c	15	19.2	80.0	676	9	AZ567762	AZ567762 238PvG10
c	16	19.2	80.0	855	10	CL980959	CL980959 OsIFCC035
c	17	19.2	80.0	951	2	BI106036	BI106036 602891028
c	18	19.2	80.0	1006	10	AG050723	AG050723 Pan trogl
	19	19.2	80.0	1075	8	DR122833	DR122833 49335251
	20	19.2	80.0	1084	2	BF139348	BF139348 601785206
c	21	19.2	80.0	1116	8	DR140741	DR140741 49335645
	22	19.2	80.0	1311	9	BH770595	BH770595 LLMGtag35
	23	19.2	80.0	1548	10	AG031110	AG031110 Pan trogl
	24	19	79.2	797	6	CF814111	CF814111 EST691493
	25	18.8	78.3	563	3	BI744510	BI744510 pb09h03.y
c	26	18.8	78.3	669	3	BI736003	BI736003 603359133
c	27	18.8	78.3	936	2	BF142544	BF142544 601789246
	28	18.8	78.3	1028	5	BX838045	BX838045 BX838045
c	29	18.8	78.3	1113	10	CL478591	CL478591 SAIL_293_
c	30	18.8	78.3	1133	10	AG070116	AG070116 Pan trogl
	31	18.8	78.3	1867	10	CG757065	CG757065 P052-2-A0
c	32	18.4	76.7	897	10	CW698279	CW698279 AIAA-aaa3
	33	18.2	75.8	120	9	CC849120	CC849120 NDL.129K1
	34	18.2	75.8	304	2	BG601514	BG601514 EST500604
c	35	18.2	75.8	377	2	BG789214	BG789214 SEAUMC009
	36	18.2	75.8	378	3	BM577231	BM577231 170006871
	37	18.2	75.8	454	3	BM284105	BM284105 ki29h11.y
c	38	18.2	75.8	483	6	CA067342	CA067342 SCJFAD101
c	39	18.2	75.8	499	10	CG058334	CG058334 PUIBT38TD
c	40	18.2	75.8	531	10	CL946110	CL946110 OsIFSB002
	41	18.2	75.8	546	5	BX602071	BX602071 BX602071
c	42	18.2	75.8	580	2	BG437267	BG437267 602490546
	43	18.2	75.8	580	3	BJ645189	BJ645189 BJ645189
	44	18.2	75.8	583	5	BX624220	BX624220 BX624220
c	45	18.2	75.8	616	10	AG133691	AG133691 Pan trogl

ALIGNMENTS

RESULT 1
AZ183817
LOCUS AZ183817 850 bp DNA linear GSS 30-AUG-2000
DEFINITION SP_1002_A1_B08_SP6 Strongylocentrotus purpuratus, purple sea urchin, sperm genomic BAC library Strongylocentrotus purpuratus genomic clone Plate=1002 Col=15 Row=C, genomic survey sequence.
ACCESSION AZ183817
VERSION AZ183817.1 GI:8356192
KEYWORDS GSS.
SOURCE Strongylocentrotus purpuratus
ORGANISM Strongylocentrotus purpuratus
Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa; Echinoidea; Euechinoidea; Echinacea; Echinoida; Strongylocentrotidae; Strongylocentrotus.
REFERENCE 1 (bases 1 to 850)
AUTHORS Cameron,R.A., Mahairas,G., Rast,J.P., Martinez,P., Biondi,T.R., Swartzell,S., Wallace,J.C., Poustka,A.J., Livingston,B.T., Wray,G.A., Ettensohn,C.A., Lehrach,H., Britten,R.J, Davidson,E.H. and Hood,L.
TITLE A sea urchin genome project: Sequence scan, virtual map, and additional resources
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (17), 9514-9518 (2000)
PUBMED 10920195
COMMENT Contact: Cameron, RA, Davidson, EH, Hood, L
Division of Biology 156-29
California Institute of Technology
Pasadena California 91125, USA
Tel: (626) 395-8421
Fax: (626) 793-3047
Email: acameron@caltech.edu
Plate: 1002 row: C column: 15
Seq primer: SP6
Class: BAC ends
High quality sequence stop: 850.

SCORE Search Results Details for Application 10613739 and Search Result us-10-613-739-1.rni.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10613739 and Search Result us-10-613-739-1.rni.

start

Go Back to previous page

```
                          GenCore version 5.1.6
                    Copyright (c) 1993 - 2005  Compugen Ltd.


OM nucleic - nucleic search, using sw model

Run on:         December 31, 2005, 00:30:40 ; Search time 94 Seconds
                                            (without alignments)
                                            453.846 Million cell updates/sec

Title:          US-10-613-739-1
Perfect score:  24
Sequence:       1 tcgtcgtttcgtcgttttgtcgtt 24

Scoring table:  IDENTITY_NUC
                Gapop 10.0 , Gapext 1.0

Searched:       1303057 seqs, 888780828 residues

Total number of hits satisfying chosen parameters:      2606114

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :        Issued_Patents_NA:*
                 1:  /cgn2_6/ptodata/1/ina/1_COMB.seq:*
                 2:  /cgn2_6/ptodata/1/ina/5_COMB.seq:*
                 3:  /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
                 4:  /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
                 5:  /cgn2_6/ptodata/1/ina/H_COMB.seq:*
                 6:  /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
                 7:  /cgn2_6/ptodata/1/ina/PP_COMB.seq:*
                 8:  /cgn2_6/ptodata/1/ina/RE_COMB.seq:*
                 9:  /cgn2_6/ptodata/1/ina/backfiles1.seq:*

      Pred. No. is the number of results predicted by chance to have a
      score greater than or equal to the score of the result being printed,
      and is derived by analysis of the total score distribution.

                                    SUMMARIES

                  %
Result            Query
   No.    Score  Match Length DB  ID                          Description
 ------------------------------------------------------------------------
     1     22.4   93.3     24  3  US-09-030-701-6              Sequence 6, Appli
     2     22.4   93.3     24  3  US-09-286-098-90             Sequence 90, Appl
     3     22.4   93.3     24  3  US-08-960-774-46             Sequence 46, Appl
     4     22.4   93.3     24  3  US-09-082-649B-3             Sequence 3, Appli
     5     22.4   93.3     24  3  US-09-082-649B-66            Sequence 66, Appl
     6     22.4   93.3     24  3  US-09-325-193A-77            Sequence 77, Appl
     7     22.4   93.3     24  3  US-09-191-170-84             Sequence 84, Appl
     8     22.4   93.3     24  3  US-09-191-170-95             Sequence 95, Appl
     9     22.4   93.3     24  3  US-09-690-921-4              Sequence 4, Appli
    10     22.4   93.3     24  3  US-09-337-619-46             Sequence 46, Appl
    11     22.4   93.3     24  3  US-09-965-101-3              Sequence 3, Appli
    12     22.4   93.3     24  3  US-09-965-101-66             Sequence 66, Appl
```

	13	22.4	93.3	24	3	US-10-057-531A-8	Sequence 8, Appli
	14	22.4	93.3	24	3	US-09-495-947-5	Sequence 5, Appli
	15	22.4	93.3	24	3	US-09-495-947-7	Sequence 7, Appli
	16	22.4	93.3	24	3	US-09-495-947-17	Sequence 17, Appl
	17	22.4	93.3	24	3	US-09-954-987B-112	Sequence 112, App
	18	22.4	93.3	24	3	US-09-954-987B-128	Sequence 128, App
	19	22.4	93.3	24	3	US-09-672-126B-2	Sequence 2, Appli
	20	22.4	93.3	24	3	US-09-672-126B-108	Sequence 108, App
	21	22.4	93.3	24	3	US-09-672-126B-147	Sequence 147, App
	22	22.4	93.3	52	3	US-09-082-649B-15	Sequence 15, Appl
	23	22.4	93.3	52	3	US-09-965-101-15	Sequence 15, Appl
	24	21.4	89.2	23	3	US-09-337-619-123	Sequence 123, App
C	25	17.6	73.3	286	3	US-09-270-767-27314	Sequence 27314, A
C	26	17.6	73.3	480	3	US-08-612-973-11	Sequence 11, Appl
C	27	17.6	73.3	480	3	US-08-927-597-11	Sequence 11, Appl
C	28	17.6	73.3	480	3	US-08-928-757-11	Sequence 11, Appl
C	29	17.6	73.3	483	3	US-08-612-973-9	Sequence 9, Appli
C	30	17.6	73.3	483	3	US-08-927-597-9	Sequence 9, Appli
C	31	17.6	73.3	483	3	US-08-928-757-9	Sequence 9, Appli
C	32	17.6	73.3	894	3	US-09-270-767-11695	Sequence 11695, A
	33	17.6	73.3	1350	3	US-09-769-787-322	Sequence 322, App
	34	17.6	73.3	25002	3	US-08-961-527-48	Sequence 48, Appl
	35	17.4	72.5	24	3	US-09-672-126B-4	Sequence 4, Appli
C	36	17.2	71.7	51905	3	US-09-949-002-667	Sequence 667, App
C	37	17.2	71.7	51905	3	US-09-949-002-781	Sequence 781, App
C	38	17	70.8	2784	3	US-09-828-313-14	Sequence 14, Appl
	39	16.8	70.0	975	3	US-09-902-540-5221	Sequence 5221, Ap
C	40	16.8	70.0	31826	3	US-09-902-540-1256	Sequence 1256, Ap
C	41	16.6	69.2	277	2	US-08-634-797-41	Sequence 41, Appl
C	42	16.6	69.2	306	2	US-08-634-797-11	Sequence 11, Appl
C	43	16.6	69.2	306	2	US-08-634-797-12	Sequence 12, Appl
C	44	16.6	69.2	306	2	US-08-634-797-14	Sequence 14, Appl
C	45	16.6	69.2	306	2	US-08-634-797-16	Sequence 16, Appl

ALIGNMENTS

```
RESULT 1
US-09-030-701-6
; Sequence 6, Application US/09030701B
; Patent No. 6214806
; GENERAL INFORMATION:
;  APPLICANT:  Krieg, Arthur M.
;  APPLICANT:  Schwartz, David A.
;  TITLE OF INVENTION:  USE OF NUCLEIC ACIDS CONTAINING
;  TITLE OF INVENTION:  UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF
;  TITLE OF INVENTION:  LPS-ASSOCIATED DISORDERS
;  FILE REFERENCE:  C1039/7011
;  CURRENT APPLICATION NUMBER: US/09/030,701B
;  CURRENT FILING DATE:  1998-02-25
;  PRIOR APPLICATION NUMBER:  60/039,405
;  PRIOR FILING DATE:  1997-02-28
;  NUMBER OF SEQ ID NOS:  65
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-030-701-6

  Query Match             93.3%;  Score 22.4;  DB 3;  Length 24;
  Best Local Similarity   95.8%;  Pred. No. 0.84;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 TCGTCGTTTCGTCGTTTTGTCGTT 24
              ||||||||| ||||||||||||||
Db          1 TCGTCGTTTTGTCGTTTTGTCGTT 24


RESULT 2
US-09-286-098-90
```